Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Abeona Therapeutics in a report issued on Monday. Jefferies Group analyst M. Raycroft forecasts that the biopharmaceutical company will post earnings of ($0.21) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $28.00 target price on the stock. Jefferies Group also issued estimates for Abeona Therapeutics’ Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.23) EPS, Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.90) EPS, FY2019 earnings at ($0.41) EPS, FY2020 earnings at $0.33 EPS and FY2021 earnings at $1.67 EPS.

How to Become a New Pot Stock Millionaire

A number of other equities research analysts have also recently commented on ABEO. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Wednesday, November 22nd. ValuEngine cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada restated a “buy” rating and set a $26.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Abeona Therapeutics presently has an average rating of “Buy” and a consensus target price of $27.33.

Shares of ABEO stock opened at $15.75 on Wednesday. The company has a market capitalization of $660.00, a price-to-earnings ratio of -23.86 and a beta of 1.30. Abeona Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.24 million. Abeona Therapeutics had a negative net margin of 3,263.92% and a negative return on equity of 24.57%. The company’s revenue was down 16.0% on a year-over-year basis.

Several hedge funds have recently bought and sold shares of the company. Viking Global Investors LP boosted its holdings in shares of Abeona Therapeutics by 80.5% during the fourth quarter. Viking Global Investors LP now owns 4,040,727 shares of the biopharmaceutical company’s stock worth $64,046,000 after purchasing an additional 1,802,007 shares during the last quarter. BlackRock Inc. raised its position in shares of Abeona Therapeutics by 15.1% in the 4th quarter. BlackRock Inc. now owns 1,868,378 shares of the biopharmaceutical company’s stock worth $29,614,000 after buying an additional 245,217 shares during the period. Vanguard Group Inc. raised its position in shares of Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock worth $6,922,000 after buying an additional 108,730 shares during the period. State Street Corp purchased a new position in shares of Abeona Therapeutics in the 2nd quarter worth $1,900,000. Finally, Geode Capital Management LLC raised its position in shares of Abeona Therapeutics by 11.4% in the 4th quarter. Geode Capital Management LLC now owns 277,958 shares of the biopharmaceutical company’s stock worth $4,405,000 after buying an additional 28,498 shares during the period. Institutional investors and hedge funds own 62.64% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/abeona-therapeutics-inc-expected-to-post-q1-2018-earnings-of-0-21-per-share-abeo/1955112.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.